pharmaphorum23h
Novo Nordisk will file semaglutide for MASH next year
Novo Nordisk's GLP-1 receptor agonist semaglutide ... placebo on top of standard care and followed for 72 weeks. MASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects between ...
pharmaphorum23h
Novo Nordisk steps up sickle cell push with $1.1bn Forma buy
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...
Wall Street Journal23h
Novo Nordisk A/S ADR
$ 84.38-0.07-0.08% ...